Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andre C Kalil

Showing results (71-80 of 277) with videos related to

Pageof 28
Sort By:
The Lancet. Respiratory Medicine|May 16, 2025
Guidelines without borders: the case for JAK inhibitors as the first-line immunomodulator COVID-19 treatmentDaniel A Sweeney, Andre C Kalil
Annals of Internal Medicine|February 17, 2015
ACP Journal Club: review: oral antiviral drugs reduce clinical recurrence in recurrent genital herpesAndre C Kalil, Uriel S Sandkovsky
Transplantation|March 29, 2011
Why valganciclovir should not be indicated for liver recipients and high-dose acyclovir should not be removed from international cytomegalovirus guidelinesAndre C Kalil, Diana F Florescu
Infectious Disorders Drug Targets|June 18, 2011
Cytomegalovirus infections in non-immunocompromised and immunocompromised patients in the intensive care unitDiana F Florescu, Andre C Kalil
Critical Care Medicine|February 4, 2022
The Puzzles of Ventilator-Associated Pneumonia and COVID-19: Absolute Knowns and Relative UnknownsJonathan H Ryder, Andre C Kalil
Chest|June 9, 2024
Changes in the Mortality Rate and Epidemiology of Pneumocystis Pneumonia Require Novel Approaches to Clinical CareSias J Scherger, Andre C Kalil
Infection Control and Hospital Epidemiology|August 4, 2010
Positive deviance and hand hygiene: more questions than answersMark E Rupp, Andre C Kalil
Current Infectious Disease Reports|May 6, 2015
Sepsis in the severely immunocompromised patientAndre C Kalil, Steven M Opal
JAMA|August 18, 2016
Secondary Infection in Patients With SepsisDaniel A Sweeney, Andre C Kalil
Current Opinion in Critical Care|August 6, 2021
Janus Kinase inhibitors for the treatment of hospitalized patients with COVID-19Diana F Florescu, Andre C Kalil
Pageof 28

Showing results (71-80 of 277) with videos related to

Sort By:
Pageof 28
The Lancet. Respiratory Medicine|May 16, 2025
Guidelines without borders: the case for JAK inhibitors as the first-line immunomodulator COVID-19 treatmentDaniel A Sweeney, Andre C Kalil
Annals of Internal Medicine|February 17, 2015
ACP Journal Club: review: oral antiviral drugs reduce clinical recurrence in recurrent genital herpesAndre C Kalil, Uriel S Sandkovsky
Transplantation|March 29, 2011
Why valganciclovir should not be indicated for liver recipients and high-dose acyclovir should not be removed from international cytomegalovirus guidelinesAndre C Kalil, Diana F Florescu
Infectious Disorders Drug Targets|June 18, 2011
Cytomegalovirus infections in non-immunocompromised and immunocompromised patients in the intensive care unitDiana F Florescu, Andre C Kalil
Critical Care Medicine|February 4, 2022
The Puzzles of Ventilator-Associated Pneumonia and COVID-19: Absolute Knowns and Relative UnknownsJonathan H Ryder, Andre C Kalil
Chest|June 9, 2024
Changes in the Mortality Rate and Epidemiology of Pneumocystis Pneumonia Require Novel Approaches to Clinical CareSias J Scherger, Andre C Kalil
Infection Control and Hospital Epidemiology|August 4, 2010
Positive deviance and hand hygiene: more questions than answersMark E Rupp, Andre C Kalil
Current Infectious Disease Reports|May 6, 2015
Sepsis in the severely immunocompromised patientAndre C Kalil, Steven M Opal
JAMA|August 18, 2016
Secondary Infection in Patients With SepsisDaniel A Sweeney, Andre C Kalil
Current Opinion in Critical Care|August 6, 2021
Janus Kinase inhibitors for the treatment of hospitalized patients with COVID-19Diana F Florescu, Andre C Kalil
Pageof 28